Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines)

Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity

(2014) K P Callahan et al.   LEUKEMIA

The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expression

(2014) M S Becker et al.   Cell Death & Disease

Evidence for a Functionally Relevant Rocaglamide Binding Site on the eIF4A–RNA Complex

(2013) Heather Sadlish et al.   ACS Chemical Biology

The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM/ATR-mediated Chk1/2 cell cycle checkpoints

(2013) Jennifer Neumann et al.   INTERNATIONAL JOURNAL OF CANCER

Synthesis of Biotinylated Episilvestrol: Highly Selective Targeting of the Translation Factors eIF4AI/II

(2013) Jennifer M. Chambers et al.   ORGANIC LETTERS

Tight Coordination of Protein Translation and HSF1 Activation Supports the Anabolic Malignant State

(2013) S. Santagata et al.   SCIENCE

IAP proteins as targets for drug development in oncology

(2013) Laurence Dubrez et al.   OncoTargets and Therapy

Suppression of eukaryotic initiation factor 4E prevents chemotherapy-induced alopecia

(2013) Zeina Nasr et al.   BMC Pharmacology & Toxicology

Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence

(2012) Tongyuan Li et al.   CELL

HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers

(2012) Marc L. Mendillo et al.   CELL

“Prohibitin”g CRAF/MAPK Activation with Rocaglamides

(2012) Krishnaraj Rajalingam et al.   CHEMISTRY & BIOLOGY

The Natural Anticancer Compounds Rocaglamides Inhibit the Raf-MEK-ERK Pathway by Targeting Prohibitin 1 and 2

(2012) Gernot Polier et al.   CHEMISTRY & BIOLOGY

Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis

(2012) Chengkai Dai et al.   JOURNAL OF CLINICAL INVESTIGATION

Flavaglines as Potent Anticancer and Cytoprotective Agents

(2012) Nigel Ribeiro et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors

(2012) Tao Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

(2012) L Y Dimberg et al.   ONCOGENE

Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53

(2011) Michelle Martinez-Rivera et al.   BIOCHEMICAL PHARMACOLOGY

The role and therapeutic potential of prohibitin in disease

(2011) Arianne L. Theiss et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Heat shock factor 1 promotes invasion and metastasis of hepatocellular carcinoma in vitro and in vivo

(2011) Feng Fang et al.   CANCER

Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression

(2011) Colleen A. Brady et al.   CELL

Apoptosis in Heart Failure

(2011) Takayuki Fujita et al.   CIRCULATION JOURNAL

Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas

(2011) Marco Giaisi et al.   INTERNATIONAL JOURNAL OF CANCER

The biological and therapeutic relevance of mRNA translation in cancer

(2011) Sarah P. Blagden et al.   Nature Reviews Clinical Oncology

Raf kinases in cancer–roles and therapeutic opportunities

(2011) G Maurer et al.   ONCOGENE

Flavaglines Alleviate Doxorubicin Cardiotoxicity: Implication of Hsp27

(2011) Yohann Bernard et al.   PLoS One

High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer

(2011) S. Santagata et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1

(2011) G Polier et al.   Cell Death & Disease

Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression

(2010) M Bleumink et al.   CELL DEATH AND DIFFERENTIATION

Prohibitins Are Required for Cancer Cell Proliferation and Adhesion

(2010) Claudia Sievers et al.   PLoS One

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo

(2009) David M. Lucas et al.   BLOOD

Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression

(2009) J Y Zhu et al.   CELL DEATH AND DIFFERENTIATION

PKC-mediated phosphorylation regulates c-FLIP ubiquitylation and stability

(2009) A Kaunisto et al.   CELL DEATH AND DIFFERENTIATION

Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2

(2009) H Christian Reinhardt et al.   CURRENT OPINION IN CELL BIOLOGY

PUMA, a potent killer with or without p53

(2009) J Yu et al.   ONCOGENE

Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol

(2009) Regina Cencic et al.   PLoS One

Timed Somatic Deletion of p53 in Mice Reveals Age-Associated Differences in Tumor Progression

(2009) George Hinkal et al.   PLoS One

CDC25A Phosphatase: a Rate-Limiting Oncogene That Determines Genomic Stability

(2008) D. Ray et al.   CANCER RESEARCH

Tumour cell survival signalling by the ERK1/2 pathway

(2008) K Balmanno et al.   CELL DEATH AND DIFFERENTIATION

Mcl-1 is a potential therapeutic target in multiple types of cancer

(2008) C. Akgul   CELLULAR AND MOLECULAR LIFE SCIENCES

ATR: an essential regulator of genome integrity

(2008) Karlene A. Cimprich et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Glucose sensing by MondoA:Mlx complexes: A role for hexokinases and direct regulation of thioredoxin-interacting protein expression

(2008) C. A. Stoltzman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA